15.1 Hospital-Acquired & Ventilator-Associated Pneumonia

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia

Key Takeaways Explain This Topic AI

Hospital-acquired pneumonia (HAP) develops ≥ 48 hours \ge 48\text{ hours} ≥ 48 hours after hospital admission in non-intubated patients, whereas ventilator-associated pneumonia (VAP) arises > 48 hours > 48\text{ hours} > 48 hours following endotracheal intubation.

Diagnostic sampling thresholds distinguish colonization from true parenchymal infection: endotracheal aspirate (ETA) requires > 10 5 CFU/mL > 10^5\text{ CFU/mL} > 1 0 5 CFU/mL , bronchoalveolar lavage (BAL) requires > 10 4 CFU/mL > 10^4\text{ CFU/mL} > 1 0 4 CFU/mL , and protected specimen brush (PSB) requires > 10 3 CFU/mL > 10^3\text{ CFU/mL} > 1 0 3 CFU/mL .

Empiric coverage for MRSA (vancomycin or linezolid) and double antipseudomonal coverage from two different antimicrobial classes are mandated when multidrug-resistant (MDR) pathogen risk factors or septic shock are present.

Core MDR risk factors include prior intravenous antibiotic therapy within 90 days, septic shock at the time of VAP onset, ARDS preceding VAP, ≥ 5 \ge 5 ≥ 5 days of hospitalization prior to VAP, and requirement for acute renal replacement therapy.

Evidence-based VAP prevention bundles require head-of-bed elevation to 30 ∘ – 45 ∘ 30^\circ\text{--}45^\circ 3 0 ∘ – 4 5 ∘ , daily spontaneous awakening and breathing trials (SAT/SBT), continuous subglottic secretion drainage, and maintenance of endotracheal tube cuff pressure between 20 – 30 cmH 2 O 20\text{--}30\text{ cmH}_2\text{O} 20 – 30 cmH 2 O .

Last updated: October 2026

Diagnostic Definitions and Nosocomial Pathophysiology

Pneumonia acquired in the healthcare setting represents one of the most common and morbid complications encountered in the intensive care unit. The 2016 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines established standardized definitions that delineate nosocomial pulmonary infections based on artificial airway status and timing:

Hospital-Acquired Pneumonia (HAP) : An acute lower respiratory tract infection occurring ≥ 48 hours \ge 48\text{ hours} ≥ 48 hours after hospital admission that was neither present nor incubating at the time of initial hospitalization, developing in a non-intubated patient.

Ventilator-Associated Pneumonia (VAP) : An acute lower respiratory tract infection developing > 48 hours > 48\text{ hours} > 48 hours following invasive endotracheal intubation and mechanical ventilation.

Note

The 2016 ATS/IDSA guidelines officially retired the category of Healthcare-Associated Pneumonia (HCAP) . Prior guidelines grouped nursing home residents, dialysis patients, and recently hospitalized individuals under HCAP, recommending uniform empiric broad-spectrum MRSA and antipseudomonal therapy. Clinical trials and retrospective analyses proved that HCAP criteria led to excessive, indiscriminate broad-spectrum antibiotic exposure without reducing mortality. Contemporary practice stratifies risk using patient-specific multidrug-resistant (MDR) risk factors and validated local microbiological surveillance rather than residential status alone.

Pathophysiologic Cascade of VAP

The pathogenetic sequence of VAP is primarily driven by the physical and immunological disruptions imposed by the endotracheal tube (ETT):

Upper Airway Bypass : The ETT prevents normal glottic closure, blunts the cough reflex, and disables mucociliary transport.

Subglottic Secretion Pooling : Contaminated oral, pharyngeal, and refluxed gastric secretions pool in the subglottic dead space directly above the inflated ETT cuff.

Microaspiration : Longitudinal folds inherent in polyvinyl chloride (PVC) cuffs permit intermittent microaspiration of contaminated subglottic fluid into the lower respiratory tract, particularly during patient repositioning, ventilator cycling, and coughing.

Biofilm Formation : Within hours of intubation, a polymicrobial polysaccharide-protein biofilm lines the inner lumen of the ETT. Shearing forces from ventilator gas flow and endotracheal suction catheters dislodge bacterial aggregates directly into distal terminal bronchioles and alveoli.

Host Defense Failure : Critically ill hosts exhibit impaired alveolar macrophage phagocytosis, alveolar epithelial injury, and surfactant dysfunction, culminating in purulent alveolar exudation, severe ventilation-perfusion ( V A / Q V_A/Q V A / Q ) mismatch, and systemic inflammatory cascade activation.

Diagnostic Sampling: Non-Invasive vs. Invasive Strategies

Establishing an accurate microbiological diagnosis in suspected VAP is critical for directing pathogen-specific therapy and facilitating early antimicrobial de-escalation. The clinical diagnosis of VAP—classically based on a new or progressive radiographic infiltrate paired with systemic signs of infection (fever or hypothermia, leukocytosis or leukopenia, and purulent sputum)—demonstrates poor diagnostic accuracy when used in isolation, frequently conflating pneumonia with atelectasis, ARDS, pulmonary infarction, or alveolar hemorrhage.

Quantitative Microbiological Sampling Thresholds

To distinguish bacterial colonization of the upper airway from true parenchymal alveolar infection, clinicians rely on quantitative culture thresholds. Each sampling modality carries a specific diagnostic colony-forming unit (CFU) cutoff:

Diagnostic Modality Invasive Technique Anatomical Site Sampled Diagnostic Threshold for VAP Advantages & Clinical Limitations

Endotracheal Aspirate (ETA) Non-invasive Central tracheobronchial tree > 10 5 CFU/mL > 10^5\text{ CFU/mL} > 1 0 5 CFU/mL ( > 100 , 000 CFU/mL > 100,000\text{ CFU/mL} > 100 , 000 CFU/mL ) Readily accessible at bedside; high sensitivity and negative predictive value ( > 90 % > 90\% > 90% ); lower specificity due to proximal colonization.

Bronchoalveolar Lavage (BAL) Invasive (Bronchoscopic or Blind Mini-BAL) Distal alveoli and terminal bronchioles ( 100 – 150 mL 100\text{--}150\text{ mL} 100 – 150 mL saline instillation) > 10 4 CFU/mL > 10^4\text{ CFU/mL} > 1 0 4 CFU/mL ( > 10 , 000 CFU/mL > 10,000\text{ CFU/mL} > 10 , 000 CFU/mL ) High diagnostic accuracy; permits rapid evaluation of intracellular organisms ( > 2 – 5 % > 2\text{--}5\% > 2 – 5% ) on Gram stain; requires bronchoscope and skilled operator.

Protected Specimen Brush (PSB) Invasive (Bronchoscopic double-catheter brush) Distal subsegmental airway epithelium > 10 3 CFU/mL > 10^3\text{ CFU/mL} > 1 0 3 CFU/mL ( > 1 , 000 CFU/mL > 1,000\text{ CFU/mL} > 1 , 000 CFU/mL ) Double sheath with biodegradable polyethylene glycol plug eliminates proximal contamination; small sample volume; high specificity.

Tip

The 2016 ATS/IDSA guidelines recommend non-invasive sampling with semiquantitative cultures as the primary diagnostic approach for suspected VAP over invasive sampling. Randomized trials (such as the Canadian Critical Care Trials Group trial) demonstrated that invasive bronchoscopic quantitative cultures did not reduce 28-day mortality, shorten ICU length of stay, or decrease mechanical ventilation duration compared to non-invasive aspirates. However, when quantitative cultures (BAL or PSB) are obtained, counts falling below the established thresholds ( < 10 4 CFU/mL < 10^4\text{ CFU/mL} < 1 0 4 CFU/mL for BAL or < 10 3 CFU/mL < 10^3\text{ CFU/mL} < 1 0 3 CFU/mL for PSB) provide strong objective rationale to safely discontinue or de-escalate empiric antimicrobial therapy, provided clinical stability is present.

ATS/IDSA Empiric Antimicrobial Therapy Guidelines

Empiric antimicrobial regimens for VAP and severe HAP must be initiated promptly upon clinical suspicion, following the collection of lower respiratory tract and blood cultures. Regimen selection is governed by three determinants: risk factors for multidrug-resistant (MDR) pathogens, local ICU antibiogram data, and patient mortality risk.

Core Risk Factors for Multidrug-Resistant (MDR) Pathogens in VAP

The presence of any of the following validated risk factors significantly elevates the likelihood of infection caused by methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa , extended-spectrum β \beta β -lactamase (ESBL)-producing Enterobacteriaceae , or carbapenem-resistant organisms:

Prior intravenous antibiotic therapy within the preceding 90 days.

Septic shock at the time of VAP onset.

Acute Respiratory Distress Syndrome (ARDS) preceding the development of VAP.

Hospitalization duration ≥ 5 days \ge 5\text{ days} ≥ 5 days prior to VAP onset.

Acute renal replacement therapy (RRT) required prior to VAP onset.

Indications for Empiric MRSA Coverage

Empiric MRSA coverage is indicated if any of the following criteria are met:

Presence of a risk factor for antimicrobial resistance (prior IV antibiotics within 90 days).

Patient is managed in an intensive care unit where > 10 – 20 % > 10\text{--}20\% > 10 – 20% of S. aureus isolates are methicillin-resistant, or where the local MRSA prevalence is unknown.

Patient is at high risk of mortality (septic shock or need for ventilatory support secondary to HAP).

Antimicrobial Selection for MRSA:

Vancomycin : Dosed 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV every 8 – 12 hours 8\text{--}12\text{ hours} 8 – 12 hours (adjusted for renal clearance), targeting an area under the curve to minimum inhibitory concentration ratio ( AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 / MIC ) of 400 – 600 mg ⋅ h/L 400\text{--}600\text{ mg}\cdot\text{h/L} 400 – 600 mg ⋅ h/L , preferably by Bayesian software; the 2020 ASHP/IDSA consensus no longer recommends trough-only targets of 15-20 mcg/mL because they increase nephrotoxicity. Requires careful therapeutic drug monitoring; carries risk of acute tubular necrosis, especially when combined with piperacillin-tazobactam.

Linezolid : Dosed 600 mg 600\text{ mg} 600 mg IV every 12 hours 12\text{ hours} 12 hours . Linezolid achieves higher penetration into pulmonary epithelial lining fluid (ELF) compared to vancomycin and causes no nephrotoxicity. Adverse effects include reversible myelosuppression (thrombocytopenia), peripheral/optic neuropathy, and risk of serotonin syndrome when co-administered with serotonergic agents.

Warning

Daptomycin is strictly contraindicated in pneumonia. Pulmonary surfactant binds directly to daptomycin, forming inactive micellar aggregates that abolish its bactericidal activity. Utilizing daptomycin for pulmonary MRSA infections results in clinical failure and increased mortality.

Indications for Double Antipseudomonal Coverage

Empiric double coverage targeting Pseudomonas aeruginosa and other resistant Gram-negative bacilli requires administering two antipseudomonal agents from distinct pharmacological classes . Indications include:

Any validated MDR risk factor (prior IV antibiotics within 90 days, septic shock, ARDS preceding VAP, ≥ 5 \ge 5 ≥ 5 days hospital stay, or acute RRT).

Hospital units where > 10 % > 10\% > 10% of Gram-negative isolates are resistant to candidate monotherapy beta-lactams.

High risk of mortality (ventilator dependence from HAP or septic shock). SUSPECTED VAP / SEVERE HAP
│
┌─────────────────────┴─────────────────────┐
▼ ▼
MDR Risk Factors Present? No MDR Risk Factors &
Prior IV antibiotics <90d - Local MRSA <10-20%
Septic shock - Local GNB resistance <10%
ARDS preceding VAP - No shock or high mortality risk
Hospital stay >=5 days │
Acute RRT prior to VAP ▼

│ Antipseudomonal Monotherapy:

│ YES - Cefepime OR
▼ - Piperacillin-tazobactam OR
TRIPLE DRUG REGIMEN: - Meropenem OR
1. MRSA Agent (Vancomycin / Linezolid) - Levofloxacin
2. Antipseudomonal Beta-Lactam
3. Second Antipseudomonal Agent
(Aminoglycoside OR Fluoroquinolone)
Empiric Regimen Architecture

Drug Class & Category Specific Agent & Standard Adult ICU Dosage Mechanism of Action & Clinical Nuances

MRSA Coverage (Glycopeptide) Vancomycin : 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV q8-12h (target AUC / MIC = 400 – 600 \text{AUC}/\text{MIC} = 400\text{--}600 AUC / MIC = 400 – 600 ) Inhibits cell wall peptidoglycan crosslinking; requires therapeutic drug monitoring; nephrotoxicity risk when combined with piperacillin-tazobactam.

MRSA Coverage (Oxazolidinone) Linezolid : 600 mg 600\text{ mg} 600 mg IV q12h Inhibits 50S ribosomal protein synthesis; excellent pulmonary epithelial lining fluid penetration; no nephrotoxicity; risk of myelosuppression and serotonin syndrome.

Antipseudomonal β \beta β -Lactam (Cephalosporin) Cefepime : 2 g 2\text{ g} 2 g IV q8h OR Ceftazidime : 2 g 2\text{ g} 2 g IV q8h Fourth-generation cephalosporin; anchor agent; dose-adjust for renal clearance to avoid neurotoxicity and encephalopathy.

Antipseudomonal β \beta β -Lactam (Penicillin/Inhibitor) Piperacillin-Tazobactam : 4.5 g 4.5\text{ g} 4.5 g IV q6h (or extended infusion 3.375 g 3.375\text{ g} 3.375 g over 4h q8h) Extended infusions optimize T > MIC T > \text{MIC} T > MIC ; broad anaerobic and Gram-negative activity; synergy with aminoglycosides.

Antipseudomonal β \beta β -Lactam (Carbapenem) Meropenem : 1 g 1\text{ g} 1 g IV q8h (extended infusion over 3h) OR Imipenem : 500 mg 500\text{ mg} 500 mg IV q6h Drug of choice if extended-spectrum β \beta β -lactamase (ESBL) producing pathogens are suspected; stable against broad-spectrum beta-lactamases.

Second Non- β \beta β -Lactam (Fluoroquinolone) Ciprofloxacin : 400 mg 400\text{ mg} 400 mg IV q8h OR Levofloxacin : 750 mg 750\text{ mg} 750 mg IV q24h Inhibits DNA gyrase and topoisomerase IV; oral bioavailability allows seamless IV-to-PO transition upon clinical recovery; risk of QTc prolongation.

Second Non- β \beta β -Lactam (Aminoglycoside) Amikacin : 15 – 20 mg/kg 15\text{--}20\text{ mg/kg} 15 – 20 mg/kg IV q24h OR Gentamicin/Tobramycin : 5 – 7 mg/kg 5\text{--}7\text{ mg/kg} 5 – 7 mg/kg IV q24h Binds 30S ribosomal subunit; concentration-dependent bactericidal synergy; poor epithelial lining fluid penetration precludes use as monotherapy.

Second Non- β \beta β -Lactam (Polymyxin) Colistin (loading 300 mg 300\text{ mg} 300 mg CBA, then 150 mg 150\text{ mg} 150 mg CBA q12h) OR Polymyxin B Disrupts bacterial cell membrane; reserved strictly for documented carbapenem-resistant Acinetobacter or P. aeruginosa .

Duration of Therapy and De-escalation

Standard 7-Day Duration : The 2016 ATS/IDSA guidelines recommend a standard 7-day course of antimicrobial therapy for patients with VAP or HAP who demonstrate clinical improvement. Multiple randomized trials established that a 7-day course yields equivalent clinical cure rates, identical 28-day mortality, and significantly fewer recurrent infections caused by resistant pathogens compared to 10- to 14-day courses, even for non-fermenting Gram-negative bacilli such as Pseudomonas aeruginosa .

Microbiological De-escalation : Empiric regimens should be narrowed within 48 to 72 hours based on definitive culture and susceptibility profiles. When negative quantitative cultures ( < 10 4 CFU/mL < 10^4\text{ CFU/mL} < 1 0 4 CFU/mL on BAL) accompany clinical improvement or an alternative diagnosis, antibiotics can be safely discontinued.

Procalcitonin (PCT) Kinetics : Serial serum procalcitonin levels, evaluated alongside clinical trajectory, guide early antimicrobial discontinuation (e.g., discontinuation when PCT drops by ≥ 80 % \ge 80\% ≥ 80% from peak or falls < 0.25 mcg/L < 0.25\text{ mcg/L} < 0.25 mcg/L ). Procalcitonin should not be used to withhold initial empiric therapy in suspected sepsis.

Evidence-Based VAP Prevention Bundles

Implementing structured, multidisciplinary care bundles substantially curtails the incidence of VAP, reduces ICU length of stay, and minimizes healthcare costs. The Institute for Healthcare Improvement (IHI) and the Society for Healthcare Epidemiology of America (SHEA) endorse the following core bundle interventions:

VAP Prevention Bundle Checklist

Head of Bed (HOB) Elevation to 30 ∘ – 45 ∘ 30^\circ\text{--}45^\circ 3 0 ∘ – 4 5 ∘ :

Physiologic Rationale : Prevents passive gastroesophageal reflux and gravity-dependent retrograde flow of gastric contents into the hypopharynx, significantly decreasing microaspiration.

Contraindications : Severe spinal trauma prior to clearance, unstable pelvic fractures, active prone positioning for ARDS, or profound hemodynamic shock requiring flat supine positioning.

Daily Sedative Interruption & Spontaneous Breathing Trials (SAT / SBT) :

Physiologic Rationale : Daily paired "wake up and breathe" protocols (Spontaneous Awakening Trials [SAT] paired with Spontaneous Breathing Trials [SBT]) reduce cumulative sedative accumulation, shorten duration of invasive mechanical ventilation, and accelerate successful extubation, thereby eliminating ETT dwell time.

Subglottic Secretion Drainage (CASS) :

Physiologic Rationale : Specialized endotracheal tubes equipped with an integrated dorsal evacuation lumen opening immediately above the cuff allow continuous or intermittent aspiration of contaminated secretions pooling in the subglottic space. Meta-analyses demonstrate a 40 – 50 % 40\text{--}50\% 40 – 50% reduction in VAP rates, particularly in patients anticipated to require ventilation for > 48 – 72 hours > 48\text{--}72\text{ hours} > 48 – 72 hours .

Endotracheal Tube Cuff Pressure Management ( 20 – 30 cmH 2 O 20\text{--}30\text{ cmH}_2\text{O} 20 – 30 cmH 2 O ) :

Physiologic Rationale : Cuff pressures must be measured continuously or intermittently with a calibrated manometer. Pressures < 20 cmH 2 O < 20\text{ cmH}_2\text{O} < 20 cmH 2 O allow microaspiration of pooled secretions around the cuff folds; pressures > 30 cmH 2 O > 30\text{ cmH}_2\text{O} > 30 cmH 2 O exceed tracheal mucosal capillary perfusion pressure ( 25 – 30 mmHg 25\text{--}30\text{ mmHg} 25 – 30 mmHg ), inducing mucosal ischemia, ulceration, chondritis, tracheomalacia, and subsequent tracheal stenosis.

Stress Ulcer Prophylaxis (SUP) Stewardship :

Physiologic Concern : Acid suppression raises gastric pH and permits gastric bacterial overgrowth, which has long been suspected of increasing VAP and C. difficile infection.

Current Evidence : In REVISE (NEJM 2024; 4,821 ventilated adults), pantoprazole 40 mg daily reduced clinically important upper GI bleeding (1.0% vs. 3.5%; HR 0.30) without changing 90-day mortality (29.1% vs. 30.9%) or increasing VAP or C. difficile infection. Earlier, SUP-ICU (NEJM 2018) found no mortality effect.

Practical Rule : Give stress ulcer prophylaxis (a PPI) to patients with bleeding risk factors, such as mechanical ventilation, coagulopathy (platelets < 50 , 000 / μ L < 50,000/\mu\text{L} < 50 , 000/ μ L or INR > 1.5 > 1.5 > 1.5 ), shock, or prior GI bleeding (the 2026 Surviving Sepsis Campaign suggests this for septic patients with risk factors), and stop it when those risk factors resolve. Low-risk patients do not need it.

Oral Hygiene Protocols & Chlorhexidine Controversies :

Clinical Evolution : While regular mechanical oral hygiene and tooth brushing are universally recommended to clear oral biofilms, routine application of chlorhexidine gluconate (CHG) oral rinses in non-cardiac surgery ICU patients has become controversial. Large meta-analyses identified a potential association between routine CHG oral decontamination and increased all-cause mortality, potentially mediated by subclinical microaspiration of chlorhexidine inducing chemical pneumonitis and acute lung injury. Current guidelines recommend mechanical brushing with sterile water or targeted antiseptic rinses, restricting CHG primarily to cardiac surgery populations.